Let me be honest with you from the start: I am not here to tell you that mushrooms will fix your brain. Your brain does not need fixing. But if you have spent years navigating the world with an ADHD or autistic brain, you already know that the tools available to you are… limited. And you have probably noticed that the psychedelic research boom happening right now has a glaring blind spot: almost none of it includes people like you.
So let’s talk about what we actually know, what we don’t, and why this conversation matters more than most researchers seem to realize.
The Default Mode Network: Where This Gets Interesting
To understand why psilocybin research matters for neurodivergent brains, you need to understand the default mode network, or DMN. Think of it as the brain’s background narrator — the network that activates when you are not focused on external tasks. It is responsible for self-referential thinking, mind-wandering, mental time travel, and the construction of your sense of self.
But critically… the DMN does not work the same way in neurodivergent brains.
Some studies investigate differences in how attention-related networks interact in ADHD. They do not show that a particular memory or moment of distraction is caused by a specific network in one person.
Autism brain-imaging research has reported differences in network connectivity, but findings vary across people and studies. A scan cannot tell us how an individual experiences self-reference or relationships.
Brain-imaging research has observed changes in brain-network activity after psilocybin, but those findings do not establish a treatment effect for ADHD or autism. A change seen in a scan is not the same thing as a demonstrated improvement in daily life.
So what happens when you modulate a network that is already operating differently?
We do not yet have a clear answer about how findings on psilocybin and the brain apply to autistic people or people with ADHD. Study samples and eligibility rules differ, and results cannot simply be assumed to apply to everyone.
These questions are worth studying. They do not establish that psilocybin helps ADHD or autistic people, or that every neurodivergent brain shares one network pattern.
ADHD: The Dopamine Problem and the Microdosing Question
ADHD and dopamine are more complicated than a simple shortage. Stimulant medication can help some people, but effects and side effects vary; it is not accurate to say it merely brings every person with ADHD to a single “baseline.” Medication decisions belong with the person and their clinician.
Microdosing refers to taking small amounts of a psychedelic. It has attracted interest for ADHD, but an informal schedule is not an established treatment protocol, and product strength and individual responses can vary.
Why? Because the anecdotal reports are exactly what ADHD brains are hungry for: improved focus without the flatness of stimulants, better emotional regulation, increased motivation for boring tasks, and a sense of “flow” that feels organic rather than chemically forced.
But here is where I have to pump the brakes. The clinical evidence for microdosing and ADHD is thin. Not nonexistent — but thin. A 2021 survey study by Hutten and colleagues found that self-reported ADHD symptoms were among the most common reasons people microdose, and that many participants reported subjective improvements. Petranker et al. published similar findings. But survey data is self-selected and uncontrolled. People who microdose and feel better report it. People who microdose and feel nothing, or feel worse, are less likely to show up in the data.
The controlled trials that do exist on microdosing — and there are now several — have generally found that the effects are small and inconsistent, with expectancy (placebo) playing a significant role. The 2021 Imperial College self-blinding study by Szigeti et al. was particularly deflating for microdosing advocates: improvements in wellbeing were real but could not be distinguished from placebo.
Does that mean microdosing does not work for ADHD? The answer remains uncertain. Naturalistic studies cannot establish cause and effect, and we should not treat research in other populations as proof of benefit for ADHD. One pair of placebo-controlled psilocybin microdosing trials did not find significant overall behavioral or subjective benefits over placebo; those trials do not settle the ADHD-specific question.
People considering supplements for focus also deserve evidence and an honest account of uncertainty. This article does not establish lion’s mane as an effective ADHD treatment or a safer substitute for prescribed care.
What I will say is this: if you have ADHD and you are microdosing, you are not crazy or irresponsible. You are running an experiment on yourself because the medical establishment has not gotten around to running it for you. Just be honest with yourself about what you know and what you are guessing.
Autism: Neural Flexibility, Pattern Recognition, and the Emotional Processing Gap
The autism-psilocybin conversation is different from the ADHD one, and in some ways more interesting.
Autistic people differ widely in how they think, feel, and respond to change. Brain-network findings are research observations, not a reliable description of every autistic person or a proven explanation for any individual’s strengths or difficulties.
The possibility that a psychedelic might affect emotional or behavioral flexibility is a research question, not proof that it will help an autistic person or create useful new connections.
And here, there is actual research. Small, early-stage, but real.
Research into psychological flexibility after psychedelic treatment raises questions worth investigating. Findings in a different study population cannot establish benefits for autistic people or tell us which outcomes matter to every individual.
A survey first published online in 2024 asked 233 self-selecting autistic participants about their most impactful psychedelic experience. Many attributed positive changes to it, while 20% reported undesirable effects. The non-experimental design and biased sampling mean the results cannot show that psychedelics caused those changes or predict how an individual will respond.
Then there is the alexithymia angle, and this one is particularly compelling.
Alexithymia means difficulty identifying and describing emotions. It is not a lack of emotion, and experiences vary; a percentage from one sample should not be treated as a diagnosis or prediction for an individual.
Researchers are studying emotional responses to psilocybin, but a benefit for alexithymia in autistic adults has not been established. Describing it as transformative would get ahead of the evidence.
But again: “could be” is doing a lot of work in that sentence. The research specifically examining psilocybin’s effects on alexithymia in autistic adults is virtually nonexistent. We are connecting dots between separate bodies of literature and hoping the picture holds up when someone finally studies it directly.
Microdosing: Why Neurodivergent People Keep Showing Up
Microdosing discussions describe different schedules, but no schedule is established here as safe or effective for ADHD or autism. A small dose can still have effects or risks, and mushroom potency can vary.
The appeal of a treatment that might ease daily demands is understandable. Claims that microdosing improves executive function, sensory processing, or neural flexibility without impairing function remain unproven.
Some people describe changes in emotion or sensory experience after microdosing. Such personal reports deserve to be heard, but they cannot establish how common an effect is or whether the substance caused it.
But anecdotes are not evidence, no matter how consistent they are. Confirmation bias is real. Community self-selection is real. The placebo response is real and powerful. I am not dismissing these reports — they matter, they should be studied, and they represent real human experience. But I am also not going to tell you they prove anything, because they do not.
Safety: What Neurodivergent Brains Need to Know
This is the section that most articles skip or treat as an afterthought. It should not be.
Sensory sensitivity. Psilocybin can alter perception and may be frightening or overwhelming. A quiet setting and a trusted person do not guarantee safety; supervised research conditions should not be treated as a recipe for unsupervised use.
Anxiety and distress. Psilocybin experiences can include anxiety, confusion, or distress. Individual risks vary, and an internet description of setting or preparation cannot determine whether use is safe for a particular person.
Medication interactions. This is critical. Many neurodivergent people take psychiatric medication, and psilocybin interacts with several classes.
Interactions with antidepressants and other psychiatric medicines are not fully understood. Do not stop or change a prescribed medicine to take psilocybin without discussing it with the prescribing clinician.
Interactions with stimulant medication are also uncertain. A clinician or pharmacist can review an individual’s medicines and health history; different neurotransmitter pathways do not make a combination automatically safe.
Lithium is a hard no. Case reports of seizures with psychedelics and lithium have been documented, and this combination should be treated as dangerous until proven otherwise.
Masking and the psychedelic experience. Some autistic people describe masking as a protective response to social demands. Claims that psilocybin reliably removes a mask or produces liberation are not established by the evidence presented here.
The Research Gap No One Talks About
Here is what frustrates me about the current state of psychedelic research: autistic and ADHD people need to be included and described clearly enough that findings can be interpreted for them.
Eligibility varies by study. Some research excludes certain diagnoses or medications for safety and study design reasons; without a systematic count, we cannot say how many autistic or ADHD participants are excluded.
The eligibility rules and participant characteristics of individual trials matter. Findings from a selected clinical study cannot automatically be generalized to every autistic person or person with ADHD.
This is not just an academic concern. Neurodivergent people have higher rates of depression, anxiety, PTSD, and substance use disorders than the general population. We are the people who arguably need new therapeutic tools the most, and we are being excluded from the research that might provide them.
Some researchers are starting to notice this gap. There are early-stage studies specifically examining psilocybin in autistic adults, and a growing number of researchers are calling for neurodivergent-inclusive trial design. But “starting to notice” is not the same as “actively fixing,” and the timeline for dedicated clinical trials is measured in years, not months.
The Self-Medication Reality
Let’s address the elephant in the room: many neurodivergent people are not waiting for the research. They are already using psilocybin — microdosing, macrodosing, or both — and making decisions based on their own experience, community knowledge, and the limited evidence available.
It makes sense to want options that respect your needs and your agency. That does not make self-medication risk-free or establish psilocybin as physiologically safe. Research settings use screening and support that are not equivalent to unsupervised use.
If you are considering psilocybin, discuss your health and medicines with a qualified clinician rather than changing treatment on your own. The U.S. National Center for Complementary and Integrative Health summarizes possible adverse effects, uncertainty and the importance of medical care.
Where We Stand
The honest summary is this:
Brain-network theories are interesting starting points, but they do not establish that psilocybin is uniquely helpful for neurodivergent people. The evidence needs direct, careful testing.
Anecdotal accounts are varied and cannot establish effectiveness or safety. They can help researchers ask better questions, but they cannot replace controlled studies.
The clinical evidence remains limited and does not establish psilocybin microdosing as a treatment for ADHD or autism. Observational reports and trials in other groups answer different questions.
Researchers should make eligibility rules and participant characteristics clear and include neurodivergent perspectives in study design. How well findings apply to specific groups remains an empirical question.
And in the gap between the promising theory and the missing evidence, real people are making real decisions about their own brains, as they have always done.
What I want — what I think most of us want — is not hype. It is not another miracle cure narrative. It is honest, rigorous research that actually includes us. Research that asks the right questions: not “does psilocybin work for depression?” but “does psilocybin work differently in brains that are already wired differently?” Not “is microdosing effective?” but “what does microdosing do to a dopamine system that is already running at a deficit?”
Until that research exists, we are left with theory, anecdote, and our own judgment. For neurodivergent people, that is not a new situation. We have always had to be our own researchers, our own advocates, our own experts on what works for brains that the medical establishment was not designed to understand.
The least we can do is be honest about where the evidence stops and the hope begins.
If you are looking for information about identification rather than treatment, read how an autism assessment works.
This article is for informational purposes only. It is not medical advice. If you are considering psilocybin use, consult a healthcare provider who understands both psychedelic medicine and neurodivergent neurophysiology — and if you cannot find one who understands both, please at least find one who is willing to learn.
